Monday Stock Trading Overview

Monday's trading session has seen significant activity among stocks across different market capitalization ranges. Notably, Tesla (NASDAQ:TSLA), Xpeng Inc (NYSE:XPEV), and Summit Therapeutics PLC (NASDAQ:SMMT) have experienced notable intraday price movements. As the market progresses, these stocks, alongside others from the mega-cap and large-cap categories, are shaping the day's financial narrative. Here's a look at some of the key stock movers, from the largest companies to those with smaller market valuations.

Mega-Cap Movers

• Tesla (TSLA): Sees continued momentum following better earnings/margins last week: 1.4% higher.

Large-Cap Stock Movers

• Summit Therapeutics PLC (SMMT): PESG Releases Market Update: +5.54%.
• MicroStrategy Inc (MSTR): Gains on strength in Bitcoin; +5.45%.
• Ke Holdings Inc (BEKE): +5.65%.
• Tencent Music Entertainment Group (TME): +4.57%.
• Coinbase Global (NASDAQ:COIN): +4.16%.
• Xpeng Inc (XPEV): +8.4%.
• NIO Inc (NIO): +8.94%.
• Affirm Holdings (NASDAQ:AFRM): +6.93%.
• Carnival Corp-Exch (NYSE:CCL): +3.97%.
• Albemarle (NYSE:ALB): +5.87%.

Mid-Cap Stock Movers

• Procept Biorobotics (PRCT): PROCEPT BioRobotics Reports Third Quarter 2024 Financial Results: +30.01%.
• AltC Acquisition (OKLO): +23.86%.
• NantKwest (NASDAQ:IBRX): +21.05%.
• Vera Therapeutics (VERA): +13.65%.
• Miniso Group Holding Ltd (MNSO): +9.65%.
• Ikonics Corp (WULF): +10.03%.
• Yandex (NASDAQ:NBIS): +10.27%.
• DJ Transportation Average (DJT): +1.01%.

Small-Cap Stock Movers

• Monte Rosa Therapeutics (GLUE): Monte Rosa inks $150 million Novartis (SIX:NOVN) deal for MRT-6160: +68.3%.
• pSivida Corp (EYPT): EyePoint reports positive DURAVYU trial results for DME: +34.32%.
• Revance Therapeutics (RVNC): +26.06%.
• Septerna Inc (SEPN): +18.89%.
• Serve Robotics (SERV): +18.4%.
• Nuscale Power (SMR): +15.89%.
• Prothena Corporation PLC (PRTA): +17.65%.
• Stratasys (NASDAQ:SSYS): +14.35%.
• nLIGHT Inc (NASDAQ:LASR): +17.33%.

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.